Buy this article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this article you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.



October 2011, Volume 41 Number 10 , p 24 - 24



A new study has found that women age 70 or older with a history of heart disease and/or diabetes who take trastuzumab for breast cancer have an increased risk of developing asymptomatic or symptomatic cardiotoxicity.Forty-five patients, ages 70 to 92, who were taking trastuzumab since 2005 were identified. Thirty-three percent of women with cardiovascular risk factors such as heart disease or diabetes developed cardiotoxicity, compared with 9.1% of women who didn't have a history of heart disease and 6.1% of those without diabetes. The study authors advise close monitoring of these patients to avoid complications.Source: Serrano C, Cortes J, De Mattos-Aruda L, et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol. 2011 Aug 9. [E-pub ahead of print].The FDA has approved oral fidaxomicin for the treatment of C. difficile-associated diarrhea (CDAD). Besides causing diarrhea, C. difficile can lead to colitis and other serious gastrointestinal

To continue reading, buy this article for just $3.95.

Have a coupon or promotional code? Enter it here: